Gianni Chessari,Ian R. Hardcastle,Jong Sook Ahn,Burcu Anil,Elizabeth Anscombe,Ruth H. Bawn,Luke D. Bevan,Timothy J. Blackburn,Ildiko Buck,Celine Cano,Benoit Carbain,Juan Castro,Ben Cons,Sarah J. Cully,Jane A. Endicott,Lynsey Fazal,Bernard T. Golding,Roger J. Griffin,Karen Haggerty,Suzannah J. Harnor,Keisha Hearn,Stephen Hobson,Rhian S. Holvey,Steven Howard,Claire E. Jennings,Christopher N. Johnson,John Lunec,Duncan C. Miller,David R. Newell,Martin E. M. Noble,Judith Reeks,Charlotte H. Revill,Christiane Riedinger,Jeffrey D. St. Denis,Emiliano Tamanini,Huw Thomas,Neil T. Thompson,Mladen Vinković,Stephen R. Wedge,Pamela A. Williams,Nicola E. Wilsher,Bian Zhang,Yan Zhao,Mladen Vinković

Abstract:Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02188</a>.Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_001.csv">CSV</a>)Model of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_002.cif">CIF</a>)Structure factors of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_003.cif">CIF</a>)Additional experimental details for compounds not included in the main section and analytical data for all compounds and intermediates; NMR studies on 5; X-ray structure tables; and computational chemistry (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of spirooxindole–ferrocene hybrids as novel MDM2 inhibitors

Small Molecule Inhibitors of the P53-Mdm2

Synthesis, crystal structure, Hirshfeld surface, computational and biological studies of spiro-oxindole derivatives as MDM2-p53 inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans As Novel P53-Mdm2 Inhibitors

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma